SCHEMBL4059673

SCHEMBL4059673

Fc1ccccc1Oc1ccc2c(-c3ccccc3)n[nH]c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 8/20 0.62
MAPK10 P53779 4/20 0.48
MAPK14 Q16539 3/20 0.48
MAPK8 P45983 2/20 0.48
TTK P33981 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
ALPL P05186 1/20 0.47
GAA P10253 1/20 0.47
IDO1 P14902 1/20 0.47
HPGD P15428 1/20 0.47
CHEK1 O14757 2/20 0.47
FGFR1 P11362 2/20 0.47
KDR P35968 2/20 0.47
CDK2 P24941 2/20 0.47
CDK4 P11802 1/20 0.47
CCNA2 P20248 1/20 0.47
CCND1 P24385 1/20 0.47
CCND3 P30281 1/20 0.47
LRRK2 Q5S007 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058556 0.97 MAP2K4 (0.59) MAP2K4MAPK10MAPK14MAPK8TTK
SCHEMBL4063919 0.90 MAP2K4 (0.50) MAP2K4MAPK10MAPK14MAPK8ALDH1A1
SCHEMBL4057539 0.90 MAP2K4 (0.50) MAP2K4MAPK10MAPK14MAPK8CHEK1
SCHEMBL4061419 0.90 PDPK1 (0.56) MAP2K4CHEK1FGFR1KDRCDK2
SCHEMBL4059067 0.90 MAP2K4 (0.50) MAP2K4MAPK10MAPK14MAPK8CHEK1
SCHEMBL4063638 0.90 MAP2K4 (0.50) MAP2K4MAPK10MAPK14MAPK8IDO1
SCHEMBL4065232 0.88 MAP2K4 (0.48) MAP2K4MAPK10MAPK14MAPK8ALDH1A1
SCHEMBL4056313 0.88 MAP2K4 (0.48) MAP2K4MAPK10MAPK14MAPK8IDO1
SCHEMBL4061854 0.88 MAP2K4 (0.48) MAP2K4MAPK10MAPK14MAPK8ALDH1A1
SCHEMBL4058909 0.87 AXL (0.49) MAP2K4TTKIDO1CHEK1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US claimed
EP-1747202-A1 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F.HOFFMANN-LA ROCHE AG (CH) 2007-01-31 EP claimed
US-20050215595-A1 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-29 US claimed
WO-2005085206-A1 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 WO claimed
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
US-20050215595-A1 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215595-A1 Indazole derivatives and methods for using the same MAPK1, MAP3K1, MAP3K7 MAP2K4 73/4885MAPK10 48/4885MAPK14 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.